Navigation Links
Study shows that administering calcium and magnesium effectively reduces neurological sensitivity
Date:5/16/2008

ROCHESTER, Minn. -- Researchers in the North Central Cancer Treatment Group (NCCTG) have shown that patients who receive intravenous calcium and magnesium before and after the chemotherapy drug oxaliplatin for the treatment of advanced colon cancer experience a significantly reduced incidence and severity of neurological side effects (neurotoxicity). This reduction increases the likelihood that patients are able to complete a full course of treatment. The findings were released May 15 as part of the 44th annual meeting of the American Society of Clinical Oncology.

There have been limited studies and anecdotal stories about the effectiveness of calcium plus magnesium in reducing neurotoxicity caused by oxaliplatin, says Daniel Nikcevich, M.D., Ph.D., an oncologist at St. Marys Duluth Clinic in Duluth, Minn., a member of NCCTG and study co-chair.

We designed a double-blind, placebo-controlled study that confirmed the effectiveness of calcium plus magnesium in reducing debilitating neurological sensitivity associated with oxaliplatin, such as pain in the hands, fingers, feet and toes. In the past, these side effects have caused patients to stop treatment and, therefore, not receive critical therapy.

Each year in the United States, 150,000 patients are diagnosed with colon cancer, and approximately 50 percent of those develop advanced colon cancer. Oxaliplatin, in combination with other chemotherapy drugs such as 5-fluorouracil (5-FU), has emerged as a standard-of-care of first-line therapy for advanced colon cancer. However, oxaliplatin can cause both acute and chronic cumulative sensory neurological problems including pain, numbness and tingling that can prevent patients from completing treatment.

In the study, 50 of the 102 patients enrolled received intravenous calcium and magnesium along with oxaliplatin-based chemotherapy, while 52 patients received oxaliplatin-based adjuvant chemotherapy for colon cancer and an intraven
'/>"/>

Contact: Traci Klein
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Page: 1 2

Related medicine news :

1. ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection)
2. Study suggests blood test can help improve treatment outcomes for breast cancer patients
3. Study takes a step toward better defining fatigue
4. Having Less Power Impairs the Mind and Ability to Get Ahead, Study Shows
5. Study finds parents use cough medicines on under-2s despite the warnings
6. CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting
7. Study Supports Popular HIV Drug Regimen
8. Duska Therapeutics Sponsored University of Pennsylvania Study Demonstrates ATP Improves Sperm Motility and In Vitro Fertilization in Animals
9. Study shows that prostate cancer increases the risk of bone fracture
10. Study Suggests Green Tea May Support the Medical Treatment of Stomach and Colon Cancer
11. Forty-Five Percent of U.S. Employees Have Gained Weight at Their Current Jobs, CareerBuilder.com Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... LSTM have called for more research to be ... children in sub-Saharan Africa. In a paper in ... Russell Stothard, working with colleagues in the department ... University, in Cleveland Ohio, University of Cambridge and ... into the joint burden of HIV/AIDS and schistosomiasis ...
(Date:4/16/2014)... NJ (April 16, 2014): Celldex Therapeutics, Inc. (NASDAQ: ... 1 study of CDX-1401 in solid tumors, including long-term ... Medicine (Vol 6 Issue 232). The data demonstrate ... clinical benefit in patients with very advanced cancers and ...
(Date:4/16/2014)... While it is well known that fertility treatments are ... that multiples are at elevated risk of premature birth, ... Fertility and Sterility . The article ... reduce the odds of multiple births and prematurity, including ...
(Date:4/15/2014)... medical mystery and in the process have found a potentially ... 1.5 million people a year. The researchers say they now understand ... been in use for more than 50 years even though ... to the microbes it attacks. , A report of ...
(Date:4/14/2014)... been made in chemotherapy over the past decade, but ... continues to be a major challenge. , Nanotechnology ... the use of nanocarriers, or capsules, that can transport ... body. , The catch? These carriers are tiny, and ...
Breaking Medicine News(10 mins):Health News:More research called for into HIV and schistosomiasis coinfection in African children 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Preterm births, multiples, and fertility treatment 2Health News:Preterm births, multiples, and fertility treatment 3Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Nano shake-up 2
... WILMINGTON, Delaware, September 2 According to a ... by MarketsandMarkets,( http://www.marketsandmarkets.com ), the global emerging lighting technologies,market ... recording an,estimated CAGR of 7.9% from 2009 to 2014. ... 39% of the total revenues. , ...
... , , SAN JOSE, Calif., Sept. ... company, today announced that its IsoFlow (TM) infusion ... Drug Administration (FDA) for the direct delivery of medications into highly ... treatment of cancer. , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090902/SF69552 ) ...
... What you need to know about vaccinations for swine flu, ... fall, Americans will face a double challenge in getting shots ... and the seasonal variety. , "Two different vaccines are ... Hay, an assistant professor of medicine at the University of ...
... , , , LA JOLLA, ... today announced that Dr. Juliet Singh, President and Chief Executive Officer ... Partners Healthcare Conference in Boston, MA on Wednesday, September 9, 2009 ... can access a live audio webcast via the Internet by visiting ...
... , , WASHINGTON, Sept. 2 Danaher ... has signed a definitive agreement with MDS Inc. (TSX: MDS; ... division of MDS, which includes a 50% ownership position in ... business, and a 100% ownership position in the former Molecular ...
... , , MOUNTAIN VIEW, Calif., Sept. ... it will participate in the following events in September: , , ... Friday, September 11, at 10:20 a.m. ET in Boston, ... 13, in Philadelphia, Late-Breaking oral platform presentation on Saturday, September ...
Cached Medicine News:Health News:MarketsandMarkets: Global Emerging Lighting Technologies Market Worth US$112.2 Billion by 2014 2Health News:MarketsandMarkets: Global Emerging Lighting Technologies Market Worth US$112.2 Billion by 2014 3Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 2Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 3Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 4Health News:Keep Your Flu Shots Straight This Fall 2Health News:Keep Your Flu Shots Straight This Fall 3Health News:Transdel Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2Health News:Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation 2Health News:Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation 3Health News:Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation 4Health News:MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences 2
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors of innovative ... protect their most important business assets, intellectual property ... Because of the highly-competitive nature of ... of the most litigious industry sectors of cases ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2
... 11, 2011 Conatus Pharmaceuticals Inc. today announced the ... private placement financing.  This financing was led by new ... participation by existing investors; Aberdare Ventures, Advent Venture Partners, ... Fund.  Conatus will use the proceeds to advance the ...
... 2011 Stryker Corporation,s (NYSE: SYK ) ... 510(k) clearance for its MDM X3 Modular Dual Mobility ... to the company,s portfolio of next-generation technologies designed to ... and address a broader patient population, including both primary ...
Cached Medicine Technology:Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing 2Stryker Receives FDA 510(k) Clearance to Market Modular Dual Mobility Acetabular (Hip) System 2Stryker Receives FDA 510(k) Clearance to Market Modular Dual Mobility Acetabular (Hip) System 3
Forceps, extra delicate, straight....
Jewelers Forceps, delicate, straight....
Cilia Forceps, slanted jaws, gold plated....
1 mm x 6 mm oval hole....
Medicine Products: